STIMMEDIUM SIGNALFINANCIAL10-K

STIM removed specific cash flow break-even guidance for Q3 2025 while showing improved but still negative operating performance and increased debt burden.

The removal of the Q3 2025 cash flow break-even target suggests management may be backing away from previous optimistic projections, which could indicate operational challenges or a more conservative outlook. Despite improved financial metrics across revenue growth and reduced losses, the company appears to be tempering investor expectations about near-term profitability milestones.

Comparing 2026-03-17 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

STIM demonstrated mixed but generally improving financial performance with revenue growing 25.2% to $15.6M and gross profit surging 33.5% to $72.3M, while net losses narrowed from -$43.7M to -$39.0M and operating cash flow improved significantly. However, the company increased its debt burden by 19.3% to $65.8M and saw stockholders' equity decline 19.2% to $22.4M, suggesting continued reliance on external financing despite operational improvements. The sharp 48.4% reduction in R&D expenses may indicate cost-cutting measures that could impact future growth prospects.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+52.4%
$18.5M→$28.1M

Cash position surged 52.4% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
-48.4%
$12.8M→$6.6M

R&D spending cut 48.4% — could signal cost discipline or concerning reduction in innovation investment.

Interest Expense
P&L
+34.3%
$5.4M→$7.3M

Interest expense surged 34.3% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
+34.3%
-$31.0M→-$20.4M

Operating cash flow surged 34.3% — exceptional cash generation, highest quality earnings signal.

Gross Profit
P&L
+33.5%
$54.2M→$72.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Accounts Receivable
Balance Sheet
-29.5%
$23.4M→$16.5M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Revenue
P&L
+25.2%
$12.4M→$15.6M

Revenue growing 25.2% — solid top-line momentum, watch margins for quality of growth.

Total Debt
Balance Sheet
+19.3%
$55.2M→$65.8M

Debt rose 19.3% — additional borrowing for investment or operations; monitor coverage ratios.

Stockholders Equity
Balance Sheet
-19.2%
$27.7M→$22.4M

Equity decreased 19.2% — buybacks or losses reducing book value, monitor solvency ratios.

Net Income
P&L
+10.8%
-$43.7M→-$39.0M

Net income grew 10.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-27
ADDED
and other applicable jurisdictions; the terms of the Company s credit facility; the Company s ability to successfully roll-out the Company s Better Me Provider Program on the planned timeline; and the Company s self-sustainability and existing cash balances.
The Company cautions investors not to place undue reliance on these forward-looking statements.
New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties.
(the Company or Neuronetics or the Registrant ) believes that mental health is as important as physical health.
As a global leader in neuroscience, the Company is delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.
+7 more — sign up free →
REMOVED
and other applicable jurisdictions; the terms of the Company s credit facility; the Company s ability to successfully roll-out the Company s Better Me Provider program on the planned timeline; the Company s self-sustainability and existing cash balances; and the Company s ability to achieve cash flow break-even in the third quarter of 2025.
Business Overview We believe that mental health is as important as physical health.
As a global leader in neuroscience, we are delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.
Our first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation ( TMS ) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The system is cleared by the United States Food and Drug Administration (the FDA ) to treat adult patients with major depressive disorder ( MDD ) who have failed to achieve satisfactory improvement from at least one prior antidepressant medication in the current MDD episode.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →